Jared M. Baeten

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

89h-index33.6kcitations704works16.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS Research and Interventions(501), HIV, Drug Use, Sexual Risk(246), Adolescent Sexual and Reproductive Health(229), HIV Research and Treatment(198), Sex work and related issues(101)

Publications682 total

Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1
Annals of Internal Medicine·2025
Integrating oral pre-exposure prophylaxis delivery in primary care family planning clinics: a pragmatic, stepped-wedge, cluster-randomised trial
The Lancet Primary Care·2025· 1 citedOpen Access
Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression
UNC Libraries·2025Open Access
<i>Trichomonas vaginalis</i> Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis
The Journal of Infectious Diseases·2025Open Access
Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study
PLoS Medicine·2025Open Access
HIV-phyloTSI: subtype-independent estimation of time since HIV-1 infection for cross-sectional measures of population incidence using deep sequence data
BMC Bioinformatics·2025Open Access
Non‐communicable disease (NCD) risk among people living with HIV in KwaZulu‐Natal, South Africa: evidence from a randomised trial of community‐based differentiated service delivery
Journal of the International AIDS Society·2025· 1 citedOpen Access
Understanding barriers and facilitators to doxycycline post-exposure prophylaxis adherence among young women in western kenya: a qualitative study
BMC Infectious Diseases·2025· 2 citedOpen Access
Opportunity for cost savings with a novel differentiated model of PrEP delivery: a comparative costing analysis of six-month PrEP supported by interim HIV self-testing and standard of care PrEP dispensing in Kenya
BMC Health Services Research·2025Open Access
Cofactors of earlier uptake of modern postpartum family planning methods in Kenya
PLOS Global Public Health·2025· 1 citedOpen Access
Lenacapavir for HIV Prevention: A Commitment to Equitable Access and Partnership by Gilead Sciences
Clinical Infectious Diseases·2025· 10 citedOpen Access
True and false positive HIV point of care test results in a prospective multinational study of at-risk African women: implications for large-scale repeat HIV testing in HIV prevention programs.
UNC Libraries·2025Open Access
Prenatal exposure to HIV pre-exposure prophylaxis and birth, growth, and social–emotional developmental outcomes throughout early childhood in Kenya: a prospective cohort study
The Lancet Global Health·2025· 1 citedOpen Access
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study
UNC Libraries·2025Open Access
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial
Carolina Digital Repository (University of North Carolina at Chapel Hill)·2025Open Access
577. Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir
Open Forum Infectious Diseases·2025· 4 citedOpen Access
Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women
UNC Libraries·2025Open Access
Integrating Pre-Exposure Prophylaxis Delivery in Primary Care Family Planning Clinics: A Pragmatic Stepped-Wedge Cluster Randomized Trial
SSRN Electronic Journal·2025Open Access
Adaptive HIV pre-exposure prophylaxis adherence interventions for young women in Johannesburg, South Africa: a sequential multiple-assignment randomised trial
The Lancet HIV·2024· 8 citedOpen Access
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
New England Journal of Medicine·2024· 172 cited
page 1 of 35Next →

Frequent Co-authors

Connie Celum(29), Nelly Mugo(15), Deborah Donnell(14), Elizabeth A. Bukusi(13), James Kiarie(10), Jairam R. Lingappa(10), Katherine K. Thomas(8), Jessica E. Haberer(8), Linda‐Gail Bekker(8), Helen Rees(8), Anna Wald(7), Renee Heffron(7), Sinéad Delany‐Moretlwe(7), Grace John‐Stewart(6), Andrew Mujugira(6), Ariane van der Straten(6), R. Scott McClelland(6), Elly Katabira(5), Edwin Were(5), Carey Farquhar(5)